

1653  
PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Harrington, et al.

Serial No.: 08/951,733

Group Art Unit No.: 1653

Filed: October 16, 1997

Examiner: Gabriele E. Bugaisky

For: NOVEL GENES ENCODING TELOMERASE  
PROTEINS

Docket No.: A-433B

RECEIVED

JAN 14 2003

COMMUNICATION

TECH CENTER 1600/2900

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Applicants hereby request an update as to the status of this pending patent application. The history of the prosecution of this patent application is set forth in the following paragraph.


The claims in this application were found to be allowable in June 2000, prosecution was suspended June 15, 2000 due to a potential interference. On July 17, 2001, U.S. Patent No. 6,261,836 B1 claiming subject matter similar to that of Applicants allowed claims was issued to Geron Corp. In a telephone conversation between the undersigned attorney for Applicants and Examiner G. Bugaisky on April 3, 2002, Examiner Bugaisky indicated that an official action for the subject patent application would be issued shortly. To date, no such official action has been received.

In the interest of advancing the prosecution of this patent application, Applicants would appreciate receiving a written status report from the USPTO as soon as practicable.

Thank you.

Please send all future correspondence to:  
U.S. Patent Operations/NAO  
Dept. 4300, M/S 27-4-A  
AMGEN INC.  
One Amgen Center Drive  
Thousand Oaks, California 91320-1799

Respectfully submitted,

  
Nancy A. Oleski  
Attorney/Agent for Applicant(s)  
Registration No.: 34,688  
Phone: (805) 447-6504  
Date: January 6, 2003

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

1/6/03  
\_\_\_\_\_  
Date

  
\_\_\_\_\_  
Signature